Interpretation of results from mutation screening of tumor suppressor genes, such as BRCA2, is becoming an increasingly important part of clinical practice. In most cases, this is quite straightforward, but classification of rare missense variants in these genes presents a difficult problem because it is not known whether these subtle changes in the proteins alter function sufficiently to predispose cells to cancer development. As missense mutations account for approximately 35% of all known variants detected by clinical mutation screening in BRCA1 and BRCA2 this has become a significant clinical genetics issue. Here we propose to evaluate and predict whether 200 relatively common BRCA2 missense mutations are disease causing or neutral using a likelihood model that depends on 1) co-segregation of the mutation with disease in affected families, 2) co-occurrence of the mutation with other known deleterious mutations, 3) family history of cancer, 4) evolutionary sequence conservation, and 5) chemical changes in the amino acid due to the mutation. Having classified a number of the 200 missense mutations, the likelihood model data will be considered as the """"""""gold standard"""""""" for disease causality and will be used to establish the sensitivity and specificity of a series of BRCA2 functional assays. The validated functional assays will subsequently be applied to the classification of 50 rare missense mutations from the DNA binding domain of BRCA2 that appears to be enriched for missense mutations. Finally, a more formal statistical approach to estimating the probability that a BRCA2 missense mutation is disease causing will be undertaken using a two-component mixture model that utilizes all of the family, functional, and sequence data. The knowledge gained during the study will improve risk assessment and counseling for carriers of the BRCA2 missense mutations and may lead to better evaluation of other missense mutations in this tumor suppressor gene. Furthermore, the data will provide valuable information about how the DNA binding domain of BRCA2 contributes to cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA116201-03
Application #
7550577
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2007-09-01
Budget End
2008-08-31
Support Year
3
Fiscal Year
2007
Total Cost
$350,064
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Wang, Liewei; Ingle, James; Weinshilboum, Richard (2018) Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study. Clin Pharmacol Ther 103:243-252
Augusto, Bianca M; Lake, Paige; Scherr, Courtney L et al. (2018) From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals. J Community Genet 9:209-215
Tu, Xinyi; Kahila, Mohamed M; Zhou, Qin et al. (2018) ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer. Mol Cancer Ther 17:2462-2472
Athreya, Arjun P; Gaglio, Alan J; Cairns, Junmei et al. (2018) Machine Learning Helps Identify New Drug Mechanisms in Triple-Negative Breast Cancer. IEEE Trans Nanobioscience 17:251-259
Wiese, Elizabeth K; Hitosugi, Taro (2018) Tyrosine Kinase Signaling in Cancer Metabolism: PKM2 Paradox in the Warburg Effect. Front Cell Dev Biol 6:79
Frank, Ryan D; Winham, Stacey J; Vierkant, Robert A et al. (2018) Evaluation of 2 breast cancer risk models in a benign breast disease cohort. Cancer 124:3319-3328
Degnim, Amy C; Winham, Stacey J; Frank, Ryan D et al. (2018) Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. J Clin Oncol 36:1840-1846
Ohmine, Seiga; Salisbury, Jeffrey L; Ingle, James et al. (2018) Aurora-A overexpression is linked to development of aggressive teratomas derived from human iPS cells. Oncol Rep 39:1725-1730
Kourtidis, Antonis; Anastasiadis, Panos Z (2018) Close encounters of the RNAi kind: the silencing life of the adherens junctions. Curr Opin Cell Biol 54:30-36
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99

Showing the most recent 10 out of 473 publications